Array BioPharma (ARRY) Receives Price Target

Array BioPharma (ARRY) : Average target price received by Array BioPharma (ARRY) is $8 with an expected standard deviation of $2.53. The most aggressive target on the stock is $13, whereas the most downbeat target is $6. 6 financial analysts are currently covering the stock.

Array BioPharma (ARRY) : 7 analysts are covering Array BioPharma (ARRY) and their average rating on the stock is 1, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.


Also, Equity analysts at the Brokerage firm Stifel Nicolaus maintains its rating on Array BioPharma (NASDAQ:ARRY). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Stifel Nicolaus raises the price target from $7 per share to $8 per share. The rating by the firm was issued on August 5, 2016.

Array BioPharma (NASDAQ:ARRY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.66 and $3.39 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.68. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.52, notching a gain of 2.62% for the day. The total traded volume was 4,531,555 . The stock had closed at $3.43 on the previous day.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.